“ú–{ˆã‰È‘åŠwˆãŠw‰ïŽGŽ Online Journal ƒƒCƒ“ƒiƒrƒQ[ƒVƒ‡ƒ“‚ð”ò‚΂·
‘–ÚŽŸ > †–ÚŽŸ > Abstract ƒz[ƒ€‚Ö–ß‚é
Abstract

‘æ14Šª 2018”N6ŒŽ@‘æ3†

‘S•¶PDF (647K)

¡˜_à

’¼ÚŒoŒûR‹ÃŒÅ–òiDOACj‚Ì“Á’¥‚ÆŽg‚¢•ª‚¯
ŸNˆä@‚Ü‚Ý, ˆÉ¨@—Y–ç, •ÐŽR@Žu˜Y
“ú–{ˆã‰È‘åŠw•t‘®•a‰@–òÜ•”

Distinguishing between Individual Direct Oral Anticoagulants on the Basis of their Specific Characteristics
Mami Sakurai, Yuya Ise and Shirou Katayama
Department of Pharmaceutical Service, Nippon Medical School Hospital

Before dabigatran was introduced in 2011, vitamin K antagonist was for nearly 50 years the only oral anticoagulant available. Including dabigatran, there are now four non-vitamin K antagonist direct oral anticoagulants (DOACs), which has greatly increased treatment options. However, the increased number of options has led to some confusion in the selection of appropriate anticoagulants in specific cases. In this paper, we outline the characteristics of each individual DOAC on the basis of recent reports.

“úˆã‘åˆã‰ïŽ 2018; 14(3), 113-120

Key words
direct oral anticoagulants, vitamin K antagonist, ischemic stroke, systemic embolism

Correspondence to
Mami Sakurai, Department of Pharmaceutical Service, Nippon Medical School Hospital, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan
E-mailFm-319@nms.ac.jp

Žó•tF2018”N3ŒŽ5“ú@Žó—F2018”N5ŒŽ16“ú

ƒƒCƒ“ƒiƒrƒQ[ƒVƒ‡ƒ“‚Ö–ß‚é ‚±‚̃y[ƒW‚̃gƒbƒv‚Ö–ß‚é